The MONTUKAST asthma medication can inhibit early changes in diabetic retinopathy, ocular disease that develops due to diabetes, in a type 1 diabetes mouse model, as researchers from the Rainbow Babies and Children's Hospital Hospital have demonstrated.and Case Western Reserve University School of Medicine (United States)
In his work, published in the magazine 'Diabetes', Montelukast interrupted the signaling of inflammatory molecules called leukotrienos.This interruption significantly reduced damage to small blood vessels and the nerves we see in the early stages of diabetic retinopathy.
"Although most therapies focus on the last stages of ocular disease in diabetes, these findings offer a very necessary approach to treat the disease much earlier. The reorientation of a medication already approved for use in children and adolescents preparesThe land for the rapid translation of these findings of animal models to human subjects, "explains the main author of the work, Rose Gubitosi-Klug.
Montelukast was effective both in prevention and deferred intervention approaches, which implies relevance for newly diagnosed diabetes patients, as well as for individuals living with larger diabetes.
"Therefore, there is a promise that a safe treatment that effectively stabilizes the airways in asthma can also preserve small blood vessels and nerve cells in diabetes. Both in our diabetes model and in asthma studies, asthma studies,This dose allows the effective suppression of chronic inflammation, which can prevent pathology, but avoids the complete inhibition of inflammation, which can compromise innate immunity, "concludes the researcher.